# Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC

> **NCT04303130** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 52 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04303130
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-31
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2020-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04303130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04303130, "Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04303130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*